| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Spero Therapeutics, Inc. (SPRO) has 10 insiders with recent SEC Form 4 filings, including 3 buys and 0 sells. SPRO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 986.9K | $2.23M | - | |
| COO | 742.5K | $1.68M | - | |
| Dir | 703.3K | $1.59M | - | |
| Dir | 101.5K | $229.3K | - | |
| Dir | 85.0K | $192.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2017 | Larkin Cristina | Chief Operating Officer | Buy | 1,500 | $14.00 | $21,000.00 | New | |
| Nov 6, 2017 | Glaxosmithkline Plc | 10% Owner | Buy | 428,571 | $14.00 | $5,999,994.00 | +30.1% | |
| Nov 6, 2017 | Breum Casper | Director | Buy | 214,285 | $14.00 | $2,999,990.00 | +24.4% |